TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Follow Up of Subjects Enrolled in Randomized Trials of Prenatal and Infancy Home Visitation
Brief Summary: The Elmira follow-up study is designed to assess the extent to which prenatal and infancy home visitation by nurses affects the life-course development of 19-year-old youth whose mothers received those services during pregnancy and the first two years of the child's life.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pathways; Assigned to Arm(s): 1
B: Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Communities That Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communities That Care | Intervention Type: BEHAVIORAL; Name: Communities That Care; Assigned to Arm(s): Communities That Care Intervention
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: home visitation | Intervention Type: BEHAVIORAL; Name: home visitation; Assigned to Arm(s): 2
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home visitation through pregnancy; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Arm Label: Home visitation through age 2; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Intervention Type: BEHAVIORAL; Name: nurse home visitation; Assigned to Arm(s): Home visitation through age 2, Home visitation through pregnancy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Longitudinal Follow Up of Subjects Enrolled in Randomized Trials of Prenatal and Infancy Home Visitation
Brief Summary: The Elmira follow-up study is designed to assess the extent to which prenatal and infancy home visitation by nurses affects the life-course development of 19-year-old youth whose mothers received those services during pregnancy and the first two years of the child's life.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Risk Reduction through Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Risk Reduction through Family Therapy | Intervention Type: BEHAVIORAL; Name: Risk Reduction through Family Therapy; Assigned to Arm(s): 1, 2
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home visitation through pregnancy; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Arm Label: Home visitation through age 2; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Intervention Type: BEHAVIORAL; Name: nurse home visitation; Assigned to Arm(s): Home visitation through age 2, Home visitation through pregnancy
C: Arm Label: Brief Advice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Not On Tobacco (N-O-T) Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Not On Tobacco (N-O-T) Program | Arm Label: Quit & Fit; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Module, Behavioral: Not On Tobacco (N-O-T) Program | Intervention Type: BEHAVIORAL; Name: Physical Activity Module; Assigned to Arm(s): Quit & Fit | Intervention Type: BEHAVIORAL; Name: Not On Tobacco (N-O-T) Program; Assigned to Arm(s): Not On Tobacco (N-O-T) Program, Quit & Fit
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: home visitation | Intervention Type: BEHAVIORAL; Name: home visitation; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants
Brief Summary: Primary objective:

To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine. The hypothesis tested is that the seroprotection rate for MMC at 28 days after the second MCC vaccination with concomitant administration of RotaTeq® is non-inferior to that without non-concomitant (sequential) administration of RotaTeq®.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
B: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
C: Arm Label: Breastfeeding; Type: OTHER; Interventions: Other: Breastfeeding | Arm Label: Breastfeeding Withheld; Type: ACTIVE_COMPARATOR; Interventions: Other: Breastfeeding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding, Breastfeeding Withheld
D: Arm Label: Group 1: Concomitant Administration; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Arm Label: Group 2: Sequential Administration; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration | Intervention Type: BIOLOGICAL; Name: NeisVac-C®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants
Brief Summary: Primary objective:

To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine. The hypothesis tested is that the seroprotection rate for MMC at 28 days after the second MCC vaccination with concomitant administration of RotaTeq® is non-inferior to that without non-concomitant (sequential) administration of RotaTeq®.


Options:
A: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: Group 1: Concomitant Administration; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Arm Label: Group 2: Sequential Administration; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration | Intervention Type: BIOLOGICAL; Name: NeisVac-C®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration
C: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo
D: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants
Brief Summary: Primary objective:

To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine. The hypothesis tested is that the seroprotection rate for MMC at 28 days after the second MCC vaccination with concomitant administration of RotaTeq® is non-inferior to that without non-concomitant (sequential) administration of RotaTeq®.


Options:
A: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L
B: Arm Label: Group 1: Concomitant Administration; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Arm Label: Group 2: Sequential Administration; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration | Intervention Type: BIOLOGICAL; Name: NeisVac-C®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix TM | Intervention Type: BIOLOGICAL; Name: Rotarix TM; Assigned to Arm(s): Rotarix Group
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States
Brief Summary: The purpose of this study will be to evaluate safety, tolerability and immunogenicity of three lots of 13-valent pneumococcal vaccine given to healthy infants. Lots will be studied for consistency of the immune response, as well as for non-inferiority and safety as compared to 7-valent Pneumococcal Conjugate Vaccine.


Options:
A: Arm Label: ProQuad®; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® | Intervention Type: BIOLOGICAL; Name: ProQuad®; Assigned to Arm(s): ProQuad®
B: Arm Label: Arm 1: ProQuad® at 9 and 12 months; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® manufactured with recombinant Human Albumin (rHA) | Arm Label: Arm 2: ProQuad® at 11 and 14 months; Type: EXPERIMENTAL; Interventions: Biological: ProQuad® manufactured with recombinant Human Albumin (rHA) | Arm Label: Arm 3: ProQuad at 12 and 15 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: ProQuad® manufactured with recombinant Human Albumin (rHA) | Intervention Type: BIOLOGICAL; Name: ProQuad® manufactured with recombinant Human Albumin (rHA); Assigned to Arm(s): Arm 1: ProQuad® at 9 and 12 months, Arm 2: ProQuad® at 11 and 14 months, Arm 3: ProQuad at 12 and 15 months
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: 7vPnC | Intervention Type: BIOLOGICAL; Name: 13-valent Pneumococcal Conjugate Vaccine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: BIOLOGICAL; Name: 7vPnC; Assigned to Arm(s): 4
D: Intervention Type: BIOLOGICAL; Name: MMRV; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: MMR (Priorix®); Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Varicella (Varilrix®); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: Study designed to evaluate the safety and efficacy of MTS compared to placebo with reference to CONCERTA® in pediatric subjects diagnosed with ADHD.


Options:
A: Arm Label: Methylphenidate Transdermal System (MTS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System (MTS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
C: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Low Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Medium Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: High Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Low Dose Methylphenidate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medium Dose Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): High Dose Methylphenidate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Brief Summary: Study designed to evaluate the safety and efficacy of MTS compared to placebo with reference to CONCERTA® in pediatric subjects diagnosed with ADHD.


Options:
A: Arm Label: HLD200 (methylphenidate); Type: EXPERIMENTAL; Interventions: Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HLD200 methylphenidate hydrochloride (MPH) Capsules; Assigned to Arm(s): HLD200 (methylphenidate) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Adhansia XR; Type: EXPERIMENTAL; Interventions: Drug: Adhansia XR | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Adhansia XR; Assigned to Arm(s): Adhansia XR | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
C: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
D: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: NWP09 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NWP09; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema
Brief Summary: The purpose of the study is to find out which is a better treatment for diabetic macular edema (DME): laser alone, laser combined with an intravitreal injection of triamcinolone, laser combined with an intravitreal injection of ranibizumab, or intravitreal injection of ranibizumab alone. At the present time, it is not known whether intravitreal steroid or anti-vascular endothelial growth factor (anti-VEGF) injections, with or without laser treatment, are better than just laser by itself. It is possible that one or both of the types of injections, with or without laser treatment, will improve vision more often than will laser without injections. However, even if better vision outcomes are seen with injections, side effects may be more of a problem with the injections than with laser. Therefore, this study is conducted to find out whether the benefits of the injections will outweigh the risks.


Options:
A: Intervention Type: DRUG; Name: Triamcinolone acetate; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
C: Arm Label: AVASTIN; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: OZURDEX; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): AVASTIN | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): OZURDEX
D: Arm Label: 0.5mg Ranibizumab plus laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab + laser | Arm Label: 0.5 mg Ranibizumab plus deferred laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab + deferred laser | Arm Label: 4 mg Triamcinolone plus laser; Type: EXPERIMENTAL; Interventions: Drug: Triamcinolone Acetonide + laser | Arm Label: Sham plus laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sham injection + laser | Intervention Type: DRUG; Name: Triamcinolone Acetonide + laser; Assigned to Arm(s): 4 mg Triamcinolone plus laser | Intervention Type: DRUG; Name: Ranibizumab + laser; Assigned to Arm(s): 0.5mg Ranibizumab plus laser | Intervention Type: DRUG; Name: Sham injection + laser; Assigned to Arm(s): Sham plus laser | Intervention Type: DRUG; Name: Ranibizumab + deferred laser; Assigned to Arm(s): 0.5 mg Ranibizumab plus deferred laser

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thromboprophylaxis During Bariatric Surgery
Brief Summary: This trial is an assessment of the efficacy of three thromboprophylaxis regimens in two types of bariatric surgery.

- gastric banding and gastric bypass on anti-Xa activity levels

The study includes two groups of 150 patients scheduled for gastric banding or gastric bypass.

Assessment of anti-Xa levels before and 4 hours after the injections from day 0 to 2 in order to determine the best prophylactic regimen allowing expected values ranged between 0.3 and 0.5 IU / ml.


Options:
A: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Therapeutic anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Prophylactic anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Prophylactic anticoagulation, Therapeutic anticoagulation
D: Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): N/A

Answer: D